The Global. Until the year 2020, ten biological medicines, which are currently used in hospitals in Spain, will lose their patent protection. Therefore, a competition will begin between the companies that manufacture the innovative biologic and the corporations that have developed a biosimilar drug for that gap in the pharmaceutical arsenal of each hospital.